Trevi Therapeutics (TRVI) AI Stock Analysis

• Market Cap: $1.32B
• Dividend Yield: N/A
• Average Volume (3M): 2.56M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.03
• Revenue Growth: N/A
• EPS Growth: 15.84%
• Country: US
• Employees: 31
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 121,776,855
• 10 Day Avg. Volume: 1,820,513
• 30 Day Avg. Volume: 2,561,308
• PEG Ratio: -0.14
• Price to Book (P/B): 4.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.87
• Enterprise Value/Market Cap: 0.39
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -13.42K
• Enterprise Value/Ebitda: -11.15
• 1Y Price Target: $20.89
• Price Target Upside: 56.48% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: ―

Trevi Therapeutics shows promise with significant clinical progress and a strong cash position, essential for sustaining operations in a pre-revenue phase. However, ongoing financial losses and valuation risks temper the outlook. The stock's technical indicators suggest strong momentum, but investors should be cautious due to potential volatility and financial risks inherent in early-stage biotechnology companies.

Positive Factors

Clinical Progress

Significant clinical progress with positive data readouts enhances the potential for regulatory approval and future commercialization of Haduvio.

Financial Stability

A strong cash position provides a runway into 2026, ensuring the company can fund its operations and clinical trials without immediate financial stress.

Regulatory Pathway

Engagement with the FDA for an End-of-Phase 2 meeting indicates progress towards regulatory approval, a critical step for market entry.

Negative Factors

Increased Net Loss

Rising net losses due to increased R&D expenses highlight financial strain, which could impact long-term sustainability if not managed.

Higher R&D Expenses

Escalating R&D costs, while necessary for development, increase financial pressure and require continued capital access to maintain operations.

Negative Cash Flow

Negative cash flow from operations necessitates reliance on external financing, posing a risk if future funding becomes challenging.

Trevi Therapeutics Business Overview & Revenue Model

Company Description

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

How the Company Makes Money

Trevi Therapeutics primarily makes money through the development and potential commercialization of its lead product candidate, Haduvio. Revenue is anticipated to be generated from product sales once Haduvio receives regulatory approval and is launched in the market. The company may also explore partnerships and licensing agreements with larger pharmaceutical companies to enhance its distribution capabilities and reach. Additionally, Trevi might earn revenue from milestone payments or royalties associated with such partnerships. However, as a clinical-stage company, Trevi Therapeutics currently does not have any products on the market and relies on funding from investors to support its research and development activities.

Trevi Therapeutics Financial Statement Overview

Summary

Trevi Therapeutics is in a typical growth stage for a biotech company, with no revenue and reliance on external financing for operations. While the strong cash position and low debt levels are positives, the ongoing operating losses and negative cash flow highlight the financial risks associated with pre-revenue biotech firms. Continued access to capital will be crucial for its long-term viability.

Income Statement

The company has consistently reported zero revenue over the past years, which is typical for early-stage biotechnology firms focusing on R&D. However, this leads to negative net income and operating losses, reflected in the negative EBIT and EBITDA. The lack of revenue growth and persistent losses are significant weaknesses.

Balance Sheet

Trevi Therapeutics maintains a strong cash position relative to its debt, indicating good liquidity. The debt-to-equity ratio is low, suggesting limited reliance on debt financing. However, the equity ratio has been declining, indicating increasing liabilities relative to assets, which could be a risk if unaddressed.

Cash Flow

The company has negative free cash flow, primarily due to its operating losses, which is common in the biotechnology industry during the development phase. Despite this, cash flow from financing remains positive, suggesting reliance on external funding to sustain operations. This presents a risk if future financing becomes less accessible.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-38.00K	-147.00K	0.00	0.00	-50.00K	-47.00K
EBITDA	-45.74M	-47.79M	-28.58M	-27.98M	-32.71M	-32.27M
Net Income	-45.86M	-47.91M	-29.07M	-29.15M	-33.94M	-32.76M
Balance Sheet
Total Assets	199.36M	110.90M	89.40M	123.02M	38.48M	47.13M
Cash, Cash Equivalents and Short-Term Investments	194.93M	107.62M	82.97M	120.51M	36.83M	45.00M
Total Debt	823.00K	1.03M	1.34M	9.18M	14.63M	14.21M
Total Liabilities	9.57M	11.26M	6.86M	15.56M	21.40M	19.85M
Stockholders Equity	189.79M	99.64M	82.55M	107.46M	17.07M	27.28M
Cash Flow
Free Cash Flow	-44.03M	-38.29M	-31.85M	-28.33M	-28.95M	-29.03M
Operating Cash Flow	-44.01M	-38.26M	-31.71M	-28.18M	-28.95M	-29.00M
Investing Cash Flow	-87.37M	-21.53M	59.43M	-107.37M	0.00	-32.00K
Financing Cash Flow	172.20M	61.48M	-7.91M	111.31M	20.77M	16.72M

Trevi Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRVI, the sentiment is Positive. The current price of 13.35 is above the 20-day moving average (MA) of 11.80, above the 50-day MA of 10.78, and above the 200-day MA of 7.61, indicating a bullish trend. The MACD of 0.72 indicates Negative momentum. The RSI at 73.75 is Negative, neither overbought nor oversold. The STOCH value of 87.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TRVI.

Trevi Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TRVI	55 Neutral	$1.32B	-25.81	-36.87%	―	―	15.84%
PRAX	54 Neutral	$4.48B	-14.43	-75.20%	―	364.98%	-25.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NKTR	48 Neutral	$1.24B	―	-180.24%	―	-32.79%	36.87%
WVE	47 Neutral	$1.17B	―	-86.51%	―	103.75%	33.84%
NUVB	45 Neutral	$2.71B	―	-52.49%	―	1137.19%	70.51%
ORIC	43 Neutral	$1.04B	―	-39.73%	―	―	4.29%